ReviewImmunology2005
Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?
Review in Immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 49 citations in OpenAlex.
- An integrin axis induces IFN-β production in plasmacytoid dendritic cells.The Journal of cell biology · 2022Article
- Diabetes mellitus associated neurovascular lesions in the retina and brain: A review.Frontiers in ophthalmology · 2022Review
- Targeting inflammation and immune activation to improve CTLA4-Ig-based modulation of transplant rejection.Frontiers in immunology · 2022Review
- Integrin-directed antibody-based immunotherapy: focus on VLA-4.Immunotherapy advances · 2021Review
- Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye.Clinical & experimental metastasis · 2013Article
- A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Article
- Combined costimulatory and leukocyte functional antigen-1 blockade prevents transplant rejection mediated by heterologous immune memory alloresponses.Transplantation · 2012Article
- Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.Inflammopharmacology · 2012Review
- Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2012Article
- Cell adhesion, inflammation and therapy: old ideas and a significant step forward.Acta pharmacologica Sinica · 2011Article
- Integrins as therapeutic targets: lessons and opportunities.Nature reviews. Drug discovery · 2010Review
- Leukocyte integrins and their ligand interactions.Immunologic research · 2009Review
- Role of beta7 integrins in intestinal lymphocyte homing and retention.Current molecular medicine · 2009Review
- Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there.Critical reviews in immunology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-alpha4 and anti-alphaL integrin chain monoclonal antibodies have shown a clear-cut beneficial effect in different animal models of autoimmune and inflammatory disorders as well as in human diseases, including multiple sclerosis, inflammatory bowel disease, and psoriasis. It has been widely assumed that this therapeutic effect is mainly consequence of the blockade of leucocyte adhesion to endothelium, inhibiting thus their extravasation and the inflammatory phenomenon. However, it is evident that both alpha4beta1 (very late antigen-4) and alphaLbeta2 (leucocyte function-associated antigen-1) integrins have additional important roles in other immune phenomena, including the formation of the immune synapse and the differentiation of T helper 1 lymphocytes. Therefore, it is very feasible that the long-term administration of blocking agents directed against these integrins to patients with inflammatory/autoimmune conditions may have undesirable or unexpected effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.